Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | EIF4E | P06730 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.37 |
| ▸ | PDE4A | P27815 | 6/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27478491 | 0.83 | CSNK2A1 (0.59) | CSNK2A1NPC1RAB9AKMO | |
| SCHEMBL2409169 | 0.80 | EIF4E (0.47) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL2406543 | 0.80 | EIF4E (0.47) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL2406550 | 0.80 | EIF4E (0.47) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL16476505 | 0.77 | MKNK1 (0.45) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL16476508 | 0.77 | MKNK1 (0.54) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL2409593 | 0.75 | EIF4E (0.43) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL2406582 | 0.75 | EIF4E (0.43) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL2406590 | 0.75 | EIF4E (0.43) | EIF4EMKNK1MKNK2GRM5PDE4D | |
| SCHEMBL255329 | 0.74 | HTR2C (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CSNK2A1 3915/4885EIF4E 3006/4885MKNK1 1294/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CSNK2A1 3712/4885EIF4E 2721/4885MKNK1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.